Regulatory – Page 10 – Alligator Bioscience

2020-09-09

Regulatory

Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015

Lund, Sweden, September 9, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months del ...

2020-08-27

Regulatory

Lund, Sweden, August 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today interim safety data from its ongoing clinical ...

2020-08-25

Regulatory

Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical d ...

2020-07-13

Regulatory

Promising safety data for ATOR-1015 "With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinica ...

2020-06-04

Regulatory

Lund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced ...

2020-06-01

Regulatory

Lund, Sweden, June 1, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 ...

2020-05-29

Regulatory

Lund, Sweden, May 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data ...

2020-04-27

Regulatory

Lund, Sweden, April 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents the status of the o ...

2020-04-23

Regulatory

Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...